Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 91

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 91
---
 Director                                        |

David Akunis,59, was appointed Chief Executive Officer, effective December 23, 2024. He has 30 years’ experiences as senior corporate executive with an extensive knowledge in company development and venture capital investment. Between September 2010 and November 2024, he served as the Managing Partner at Medvest UK LLP, a UK based Fund investing in Israeli Life-Sciences companies where he oversaw and managed portfolio companies and, from July 2018 through August 2024, he also served as General Manager of Flometrica, Ltd. a Medvest’s portfolio company in the digital health area with a device for diagnose and monitoring patients with Lower Urinary Track Symptoms (LUTS) from home. From July 2008 through August 2010, he was Chief Executive Officer at Seamvad Ltd., company that developed automatic vascular closer device for open surgery and endovascular procedures in which he was personally invested. From May 2006 through December 2008, he was Chief Executive Officer of Exerflow Medical Ltd., a home-care rehabilitation assist device for Cardiovascular patients which was ultimately bought out by other shareholders. From April 2001 to October 2005, he was V.P at Atid Ventures Ltd., a holding company that was invested in medical equipment companies, which was eventually sold to a Canadian fund. From April 1995 through December 1999 he worked at the Israel Export Institute, a semi governmental entity charged with assisting exporters in their businesses.

David received his B.A. in Humanities & Psychology from Tel-Aviv University in 1991, an LL.B in Law from Netanya college (Branch of Bar-Ilan University) in 1996 and his LL.M in Law from Ba-Ilan University in 2004.

Inna Martin, 49, has joined the Company as Chief Executive Officer, President and director in November 2019 and served as Chief Executive Officer through December 22, 2024, whereupon she resigned from such position, but continues to serve as a director and President of the Company. Since December 17, 2024, she is serving as Chief Operating Officer. Ms. Martin has an extensive experience of more than 20 years in healthcare and project management.Between December 2022 and February 2024, she served on the board of directors of IR Med, Inc. (OTCQB: IRME), a clinical stage medical device company focused on the development of infrared spectroscopy and AI analysis technology platform